Fill It Up: Pfizer To Consider More Flexible Deals, Alliances To Bolster Pipeline
Executive Summary
Acknowledging a lack of depth in the late-stage pipeline, Pfizer CEO Jeff Kindler said the company will use creative deal structures to add innovative drugs and biotherapeutics to its portfolio, despite the competitive market and resulting high prices for such products
You may also be interested in...
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2008
Highlights from the Q2 2008 review of pharmaceutical and biotechnology dealmaking: Despite the dearth in biopharmaceutical financings in the quarter (total money raised was just $2 billion) acquisitions thrived with total M&A volume of $11.8 billion. And biopharma alliance activity reached $2.7 billion in potential deal value during 2008's second quarter with only a handful more deals than the first quarter, but a 43% increase in dollar volume.
As Pfizer Closes Door On Exubera, Has Window Opened For Others?
Pfizer's decision to terminate its Exubera program - the first inhaled insulin product to hit the market - could provide an opportunity for other drug makers looking to step into the market, especially those prepared to address obstacles illuminated by Pfizer
As Pfizer Closes Door On Exubera, Has Window Opened For Others?
Pfizer's decision to terminate its Exubera program - the first inhaled insulin product to hit the market - could provide an opportunity for other drug makers looking to step into the market, especially those prepared to address obstacles illuminated by Pfizer